PMID- 24918788
OWN - NLM
STAT- MEDLINE
DCOM- 20140908
LR  - 20221207
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 126
IP  - 3
DP  - 2014 May
TI  - The impact of weight loss on weight-related quality of life and health 
      satisfaction: results from a trial comparing canagliflozin with sitagliptin in 
      triple therapy among people with type 2 diabetes.
PG  - 7-15
LID - 10.3810/pgm.2014.05.2752 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is primarily a self-managed disease in which 
      self-care behaviors play an important role in achieving optimal outcomes. Because 
      self-care does not result in immediate tangible or noticeable benefits, adherence 
      to such a regimen can be confusing, difficult, and frustrating. People are more 
      likely to adhere to treatment regimens that offer benefits from the patient 
      perspective, such as convenience, avoidance of hypoglycemic episodes, and weight 
      loss, compared with regimens that do not. In this study, we explored the impact 
      of the average weight loss amount demonstrated with canagliflozin treatment on 
      improvement in 3 patient-relevant outcomes that have been linked to performance 
      of healthy behaviors and better outcomes in T2DM: weight-related quality of life, 
      as measured by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) 
      questionnaire, and satisfaction with physical health and emotional health, as 
      measured by the Current Health Satisfaction Questionnaire (CHES-Q), using data 
      from a previously reported study. Weight loss of an amount demonstrated in 
      clinical trials of canagliflozin was associated with improvements in 
      weight-related quality of life and satisfaction with physical and emotional 
      health, concepts shown to be important to the persistent and consistent 
      performance of healthy behaviors.
FAU - Traina, Shana
AU  - Traina S
AD  - Janssen Global Services, LLC, Raritan, NJ. straina@its.jnj.com.
FAU - Guthrie, Robert
AU  - Guthrie R
FAU - Slee, April
AU  - Slee A
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Thiophenes)
RN  - 0 (Triazoles)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Body Weight
MH  - Canagliflozin
MH  - Diabetes Mellitus, Type 2/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucosides/administration & dosage/*therapeutic use
MH  - Glycated Hemoglobin
MH  - Health Behavior
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Personal Satisfaction
MH  - Pyrazines/administration & dosage/*therapeutic use
MH  - *Quality of Life
MH  - Self Efficacy
MH  - Sex Factors
MH  - Sexual Behavior
MH  - Sitagliptin Phosphate
MH  - Thiophenes/administration & dosage/*therapeutic use
MH  - Triazoles/administration & dosage/*therapeutic use
MH  - Weight Loss/*drug effects
EDAT- 2014/06/12 06:00
MHDA- 2014/09/10 06:00
CRDT- 2014/06/12 06:00
PHST- 2014/06/12 06:00 [entrez]
PHST- 2014/06/12 06:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
AID - 10.3810/pgm.2014.05.2752 [doi]
PST - ppublish
SO  - Postgrad Med. 2014 May;126(3):7-15. doi: 10.3810/pgm.2014.05.2752.